According to Clarivate epidemiology, more than 30 million people in the United States suffer from migraines. Despite being underused, migraine prophylaxis is a core treatment approach to reduce the frequency, severity, and duration of migraines. Prescription options include a diverse mix of on- and off-label oral drugs, AbbVie / Allergan’s Botox, and multiple anti-CGRP monoclonal antibodies (MAbs). Prophylaxis is both individualized and dynamic as physicians adjust regimens to improve outcomes and/or avoid side effects. Understanding this patient journey provides needed context for new and existing players as the prophylactic therapy market prepares for the entry of new oral CGRP receptor antagonists—namely, Biohaven’s Nurtec ODT and AbbVie / Allergan’s atogepant.
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Markets covered: United States
Key companies: Amgen / Novartis, Eli Lilly, Teva, Lundbeck, AbbVie / Allergan, Supernus Pharmaceuticals, Upsher-Smith, and Janssen-Cilag
Key drugs: Aimovig, Emgality, Ajovy, Vyepti, Botox, Trokendi XR, Qudexy XR, topiramate IR/XR, propranolol, amitriptyline, and verapamil
The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and quarterly data refreshes.